Partnered for success
The technology behind the transformation of chronic care strategies has been developed by our partner Akina, Inc., a leader in the field of polymers and hydrogels for controlled drug delivery. Their patents, and patent pending advancements, improve the patient experience and bring value to the manufacturers. They will lead the work to gain FDA approval of the three medicines Sustained Release is targeting in the first phase.
- type II diabetes (Bydureon),
- prostate and breast cancer (luteinizing-hormone releasing hormone agonist)
- an abuse deterrent pain medication (oxycodone)
The Hydrogel Template Strategy (HTS) developed by Akina produces micro-sized containers made of polymers of PLGA, poly(lactic-co-glycolic acid) that are filled with pharmaceutical compounds. The resulting steady, measured drug delivery eliminates the burst effect of current technology. It also extends the time between injections over a significantly longer period of time, up to one year, than any timed release technology in the marketplace today.
Akina’s founder, Kinam Park, Ph. D., has devoted his career to pharmaceutical innovation. He was recognized by the Controlled Release Society for his service in 2015, and serves as the editor-in-chief of their peer reviewed journal.
The Sustained Release technology is a broad based platform delivery system for pharmaceutical compounds. Where first generation time release technology relies on difficult to control processes Akina has developed a process more akin to the production of micro circuits. Using photolithography and a unique Hydrogel Template Strategy (HTS) to produce PLGA micro structures and containers.
The polymers used are identical to those used by current technology, but the containers are engineered to behave in controlled ways breaking down and releasing the medicine into the body on a more precise time line.
Medicines are combined with the polymer containers which results in very little production loss, <5% vs 60% and with lower overall production cost. These containers can be designed for the unique properties of each drug resulting in a better patient experience than is currently possible.
HTS can even be used for proteins like hormones which current technology can't do. HTS has been applied to several drugs already and preparation for large scale production of sensitive drugs without compromising their biological activity and pharmaceutical efficacy is underway.
Learn more about HTS and the work of Akina and Dr. Kinam Park through a selection of journal articles.